Argonautica Private Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$539K Buy
14,665
+2,004
+16% +$95K 0.16% 119
2025
Q4
$644K Buy
12,661
+3,990
+46% +$204K 0.19% 102
2025
Q3
$481K Buy
8,671
+559
+7% +$32.7K 0.14% 122
2025
Q2
$560K Sell
8,112
-78
-1% -$5.31K 0.18% 106
2025
Q1
$569K Buy
8,190
+726
+10% +$60K 0.2% 101
2024
Q4
$642K Sell
7,464
-27
-0.4% -$2.92K 0.21% 94
2024
Q3
$892K Buy
7,491
+43
+0.6% +$5.74K 0.3% 71
2024
Q2
$1.06M Sell
7,448
-1
-0% -$133 0.36% 62
2024
Q1
$956K Buy
7,449
+1,655
+29% +$197K 0.34% 66
2023
Q4
$599K Sell
5,794
-18
-0.3% -$1.78K 0.25% 84
2023
Q3
$529K Buy
5,812
+24
+0.4% +$2.11K 0.24% 83
2023
Q2
$468K Buy
5,788
+922
+19% +$75.3K 0.21% 92
2023
Q1
$387K Sell
4,866
-1,142
-19% -$81K 0.2% 97
2022
Q4
$407K Buy
+6,008
New +$352K 0.21% 91

Other funds holding NVO

Argonautica Private Wealth Management's NVO Position: Q1 2026 in Review

Argonautica Private Wealth Management increased its Novo Nordisk (NVO) stake by 16% in Q1 2026, buying an estimated $95K and bringing the position to 14,665 shares worth $539K. The position accounts for 0.16% of the portfolio, ranked #119.

Argonautica Private Wealth Management first reported a position in NVO in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.06M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Argonautica Private Wealth Management held 14,665 shares of Novo Nordisk worth $539K as of Q1 2026.
  • Argonautica Private Wealth Management bought 2,004 Novo Nordisk shares in Q1 2026, an estimated $95K.
  • Novo Nordisk made up 0.16% of Argonautica Private Wealth Management's portfolio in Q1 2026, its #119 holding.
  • Argonautica Private Wealth Management first reported a position in Novo Nordisk in Q4 2022 and has held it in 14 quarters since.
  • Argonautica Private Wealth Management's Novo Nordisk position peaked at $1.06M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Argonautica Private Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.